Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)
OUTLINE: This is a multi-center study.
- Pemetrexed 500 mg/m2 i.v. q 3 wks
All patients will also receive folic acid 350-1000 mcg. po once daily beginning
approximately 1 week prior to the first dose of pemetrexed and continuing until completion
of pemetrexed, Vitamin B12 1000 mcg. IM every 9 weeks beginning approximately 1 week prior
to the first dose of pemetrexed and continuing until completion of pemetrexed, and
dexamethasone 4 mg po bid the day before, the day of, and the day following each treatment
with pemetrexed
Chest x-ray will be performed prior to each cycle (if other disease assessment by imaging is
not performed) in order to ensure patients are not rapidly progressing.
Cycles are repeated every 3 weeks for up to 6 cycles or PD or intolerable side effects.
Performance Status: ECOG 0, 1, or 2
Life Expectancy: Not specified
Hematopoietic:
- WBC > 3000/mm3
- ANC > 1500/mm3
- Platelet count > 100,000/mm3
- Hemoglobin > 8 g/dL
Hepatic:
- Bilirubin < 1.0 X upper limit of normal
- Aspartate aminotransferase (AST, SGOT) < 2.5 x upper limit of normal. AST may be < 5 x
upper limit of normal for patients with liver metastasis
Renal:
- Creatinine clearance of > 45 ml/ min (by Cockcroft-Gault)
Cardiovascular:
- No unstable or uncompensated cardiovascular conditions
Pulmonary:
- No unstable or uncompensated respiratory conditions
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
- To estimate the clinical benefit rate (CR, PR, SD) of pemetrexed in two patient populations with small cell lung cancer: chemosensitive and chemoresistant relapsed independently.
12 months
No
Nasser Hanna, M.D.
Study Chair
Hoosier Oncology Group, LLC
United States: Institutional Review Board
HOG LUN04-78
NCT00216216
January 2005
October 2005
Name | Location |
---|---|
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
Siteman Cancer Center | Saint Louis, Missouri 63110 |
Center for Cancer Care at Goshen Health System | Goshen, Indiana 46526 |
Helen F. Graham Cancer Center | Newark, Delaware 19713 |
Methodist Cancer Center | Omaha, Nebraska 68114 |
Arnett Cancer Care | Lafayette, Indiana 47904 |
Northern Indiana Cancer Research Consortium | South Bend, Indiana |
Medical & Surgical Specialists, LLC | Galesburg, Illinois 61401 |
Northern Indiana Oncology Associates | South Bend, Indiana 46617 |
Oncology Hematology Associates of SW Indiana | Evansville, Indiana 47714 |
Elkhart Clinic | Elkhart, Indiana 46515 |
Community Regional Cancer Center | Indianapolis, Indiana 46256 |
Medical Consultants, P.C. | Muncie, Indiana 47303 |
Center for Cancer Care, Inc., P.C. | New Albany, Indiana 47150 |
AP&S Clinic | Terre Haute, Indiana 47804 |
Fort Wayne Oncology & Hematology, Inc | Fort Wayne, Indiana 46815 |